Diabetes coverage is improving, but could a shake-up be on the way with Novo’s oral semaglutide?
admin 5th March 2019 Uncategorised 0Payer pressure has been squeezing diabetes drugs, leading to some major sales difficulties and layoff rounds. As Bernstein analyst Wimal Kapadia observes, things are on the mend in terms of 2019 formulary coverage, but one drug could “disrupt them all.”
More: Diabetes coverage is improving, but could a shake-up be on the way with Novo’s oral semaglutide?
Source: fierce